Skip to main content
Erschienen in: Familial Cancer 1/2012

01.03.2012 | Short Communication

A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours

verfasst von: Lyn Schofield, Fabienne Grieu, Jack Goldblatt, Benhur Amanuel, Barry Iacopetta

Erschienen in: Familial Cancer | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

We have previously established in a large retrospective study that testing for microsatellite instability (MSI) in colorectal cancer (CRC) from patients aged <60 years was an effective first screen to identify individuals with Lynch syndrome (LS). From these findings, MSI and/or immunohistochemical (IHC) screening was recommended for all newly diagnosed CRC patients aged <60 years in Western Australia, regardless of family history of cancer. In the current study we evaluated the utility of routine MSI/IHC screening by diagnostic pathology laboratories for the detection of previously undiagnosed individuals and families with LS. From January 2009 to December 2010, 270 tumours were tested for MSI and for expression of MLH1, PMS2, MSH2 and MSH6 using IHC. Cases showing MSI and/or loss of expression were also tested for the BRAF V600E hotspot mutation. Seventy cases were found to have MSI, of which 25 were excluded from further investigation as possible LS cases due to presence of the BRAF V600E mutation. The remaining 45 “red flag” cases were eligible for germline testing based on their MSI, IHC and BRAF status. From 31 cases tested to date, 15 germline mutations have been found. Thirteen were from individuals not previously recognized as LS and two were untested members from known LS families. Extrapolation of the mutation incidence (15/31, 48%) to all red flag cases (n = 45) suggests that approximately 22 mutation carriers exist in this cohort. This value approximates the number of CRC cases due to LS that could be expected to arise in the Western Australian population over a two-year period (n = 24), assuming that 1% of all CRCs are due to LS. Although further improvements in workflow can be made, our preliminary findings following the implementation of state-wide routine MSI and IHC testing in Western Australia indicate that the majority of LS cases are being identified.
Literatur
1.
Zurück zum Zitat Cunningham J, Kim C, Christensen E, Tester D, Parc Y, Burgart L, Halling K, McDonnell S, Schaid D, Walsh V et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Human Genet 69:780–790CrossRef Cunningham J, Kim C, Christensen E, Tester D, Parc Y, Burgart L, Halling K, McDonnell S, Schaid D, Walsh V et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Human Genet 69:780–790CrossRef
2.
Zurück zum Zitat Katballe N, Christensen M, Wikman F, Ørntoft F, Laurberg S (2002) Frequency of hereditary nonpolyposis colorectal cancer in Danish colorectal cancer patients. Gut 50:43–51PubMedCrossRef Katballe N, Christensen M, Wikman F, Ørntoft F, Laurberg S (2002) Frequency of hereditary nonpolyposis colorectal cancer in Danish colorectal cancer patients. Gut 50:43–51PubMedCrossRef
3.
Zurück zum Zitat Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, Xicola R, Rodriguez-Moranta F, Paya A, Jover R et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. J Am Med Assoc 293:1986–1994CrossRef Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, Xicola R, Rodriguez-Moranta F, Paya A, Jover R et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. J Am Med Assoc 293:1986–1994CrossRef
4.
Zurück zum Zitat Aaltonen L, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, Chadwick R, Kääriäinen H, Eskelinen M, Järvinen H et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Eng J Med 338:1481–1487CrossRef Aaltonen L, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, Chadwick R, Kääriäinen H, Eskelinen M, Järvinen H et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Eng J Med 338:1481–1487CrossRef
5.
Zurück zum Zitat Vasen H, Taal B, Nagengast F, Griffioen G, Menko F, Kleibeuker J, Offerhaus G, Meera Khan P (1995) Hereditary non-polyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 31A(7–8):1145–1148PubMedCrossRef Vasen H, Taal B, Nagengast F, Griffioen G, Menko F, Kleibeuker J, Offerhaus G, Meera Khan P (1995) Hereditary non-polyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 31A(7–8):1145–1148PubMedCrossRef
6.
Zurück zum Zitat Järvinen H, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen L, Peltomäki P, Chapelle ADL, Mecklin J (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRef Järvinen H, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen L, Peltomäki P, Chapelle ADL, Mecklin J (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRef
7.
Zurück zum Zitat Vasen H, Watson P, Mecklin J, Lynch H (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef Vasen H, Watson P, Mecklin J, Lynch H (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef
8.
Zurück zum Zitat Umar A, Boland C, Terdiman J, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor N, Burgart L, Hamelin R et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Nat Cancer Inst 96:261–268PubMedCrossRef Umar A, Boland C, Terdiman J, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor N, Burgart L, Hamelin R et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Nat Cancer Inst 96:261–268PubMedCrossRef
9.
Zurück zum Zitat Lynch H, Riley B, Weismann S, Coronel S, Kinarsky Y, Lynch J, Shaw T, Rubinstein W (2004) Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 100:53–64PubMedCrossRef Lynch H, Riley B, Weismann S, Coronel S, Kinarsky Y, Lynch J, Shaw T, Rubinstein W (2004) Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 100:53–64PubMedCrossRef
10.
Zurück zum Zitat Kievit W, de Bruin J, Adang E, Ligtenberg M, Nagengasi F, van Krieken J, Hoogerbrugge N (2004) Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: A meta-analysis. Clin Genet 65:308–316PubMedCrossRef Kievit W, de Bruin J, Adang E, Ligtenberg M, Nagengasi F, van Krieken J, Hoogerbrugge N (2004) Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: A meta-analysis. Clin Genet 65:308–316PubMedCrossRef
11.
Zurück zum Zitat Terdiman J (2005) It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology 129:741–744PubMed Terdiman J (2005) It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology 129:741–744PubMed
12.
Zurück zum Zitat Schofield L, Watson N, Grieu F, Li W, Zeps N, Harvey J, Stewart C, Abdo M, Goldblatt J, Iacopetta B (2009) Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 124:1097–1102PubMedCrossRef Schofield L, Watson N, Grieu F, Li W, Zeps N, Harvey J, Stewart C, Abdo M, Goldblatt J, Iacopetta B (2009) Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 124:1097–1102PubMedCrossRef
13.
Zurück zum Zitat Deng G, Bell I, Crawley S, Gum J, Terdiman J, Allen B, Truta B, Sleisenger M, Kim Y (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191–195PubMedCrossRef Deng G, Bell I, Crawley S, Gum J, Terdiman J, Allen B, Truta B, Sleisenger M, Kim Y (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191–195PubMedCrossRef
14.
Zurück zum Zitat Domingo E, Laiho P, Ollikäinen M, Pinto M, Wang L, French AJ, Westra J, Frebourg T, Espín E, Armengol M et al (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 4:664–668CrossRef Domingo E, Laiho P, Ollikäinen M, Pinto M, Wang L, French AJ, Westra J, Frebourg T, Espín E, Armengol M et al (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 4:664–668CrossRef
15.
Zurück zum Zitat Percesepe A, Borghi F, Menigatti M, Losi L, Foroni M, Di Gregorio C, Rossi G, Pedroni M, Sala E, Vaccina F et al (2001) Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 19:3944–3950PubMed Percesepe A, Borghi F, Menigatti M, Losi L, Foroni M, Di Gregorio C, Rossi G, Pedroni M, Sala E, Vaccina F et al (2001) Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 19:3944–3950PubMed
16.
Zurück zum Zitat Samowitz W, Curtin K, Lin H, Robertson M, Schaffer D, Nichols M, Gruenthal K, Leppert M, Slattery M (2001) The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 121:830–838PubMedCrossRef Samowitz W, Curtin K, Lin H, Robertson M, Schaffer D, Nichols M, Gruenthal K, Leppert M, Slattery M (2001) The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 121:830–838PubMedCrossRef
18.
Zurück zum Zitat Watson N, Grieu F, Morris M, Harvey J, Stewart C, Schofield L, Goldblatt J, Iacopetta B (2007) Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn 9:472–478PubMedCrossRef Watson N, Grieu F, Morris M, Harvey J, Stewart C, Schofield L, Goldblatt J, Iacopetta B (2007) Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn 9:472–478PubMedCrossRef
19.
Zurück zum Zitat Li W, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5:2PubMedCrossRef Li W, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5:2PubMedCrossRef
20.
Zurück zum Zitat Canard G, Lefevre H, Colas C, Coulet F, Svrcek M, Lascols O, Hamelin R, shields C, Duval A, Flejou J-F,Soubrier F, Tiret E, Parc Y (2011) Screening for Lynch Syndrome in colorectal cancer: are we doing enough? Ann Surg Oncol (Published online ahead of print) doi:10.1245/s10434-011-2014-7 Canard G, Lefevre H, Colas C, Coulet F, Svrcek M, Lascols O, Hamelin R, shields C, Duval A, Flejou J-F,Soubrier F, Tiret E, Parc Y (2011) Screening for Lynch Syndrome in colorectal cancer: are we doing enough? Ann Surg Oncol (Published online ahead of print) doi:10.​1245/​s10434-011-2014-7
21.
Zurück zum Zitat Hampel H, Frankel W, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior T, Westman J et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Eng J Med 352:1851–1860CrossRef Hampel H, Frankel W, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior T, Westman J et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Eng J Med 352:1851–1860CrossRef
22.
Zurück zum Zitat Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H, Eskelinen M, Härkőnen N, Julkunen R, Kangas E, Ojala S et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193–2200PubMed Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H, Eskelinen M, Härkőnen N, Julkunen R, Kangas E, Ojala S et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193–2200PubMed
23.
Zurück zum Zitat Muller A, Giuffre G, Edmonston T, Mathiak M, Roggendorf B, Heinmoller E, Brodegger T, Tuccari G, Mangold E, Buettner R et al (2004) Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Mol Diagn 6:308–315PubMedCrossRef Muller A, Giuffre G, Edmonston T, Mathiak M, Roggendorf B, Heinmoller E, Brodegger T, Tuccari G, Mangold E, Buettner R et al (2004) Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Mol Diagn 6:308–315PubMedCrossRef
24.
Zurück zum Zitat Overbeek L, Ligtenberg M, Willems R, Hermens R, Blokx W, Dubois S, van der Linden H, Meijer J, Mlynek-Kersjes M, Hoogerbrugge N et al (2008) Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 32:1246–1251PubMedCrossRef Overbeek L, Ligtenberg M, Willems R, Hermens R, Blokx W, Dubois S, van der Linden H, Meijer J, Mlynek-Kersjes M, Hoogerbrugge N et al (2008) Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 32:1246–1251PubMedCrossRef
25.
Zurück zum Zitat Ferreira S, Claro I, Lage P, Filipe B, Fonseca R, Sousa R, Francisco I, Chaves P, Albuquerque C, Leitao C (2008) Colorectal adenomas in young patients: microsatellite instability is not a useful marker to detect new cases of Lynch syndrome. Dis Colon Rectum 51:909–915PubMedCrossRef Ferreira S, Claro I, Lage P, Filipe B, Fonseca R, Sousa R, Francisco I, Chaves P, Albuquerque C, Leitao C (2008) Colorectal adenomas in young patients: microsatellite instability is not a useful marker to detect new cases of Lynch syndrome. Dis Colon Rectum 51:909–915PubMedCrossRef
26.
Zurück zum Zitat Stoffel E, Syngal S (2005) Adenomas in young patients: what is the optimal evaluation? Am J Gastroenterology 100:1150–1153CrossRef Stoffel E, Syngal S (2005) Adenomas in young patients: what is the optimal evaluation? Am J Gastroenterology 100:1150–1153CrossRef
27.
Zurück zum Zitat Shia J, Klimstra D, Nafa K, Offit K, Guillem J, Markowitz A, Gerald W, Ellis N (2005) Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 29:96–104PubMedCrossRef Shia J, Klimstra D, Nafa K, Offit K, Guillem J, Markowitz A, Gerald W, Ellis N (2005) Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 29:96–104PubMedCrossRef
Metadaten
Titel
A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours
verfasst von
Lyn Schofield
Fabienne Grieu
Jack Goldblatt
Benhur Amanuel
Barry Iacopetta
Publikationsdatum
01.03.2012
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2012
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9494-2

Weitere Artikel der Ausgabe 1/2012

Familial Cancer 1/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.